Matthew Frank, MD, PhD


Lori Muffly, MD, MS

Exploring Minimal/Measurable Residual Disease (MRD)

Join us as we speak to Dr. Lori Muffly and Dr. Matthew Frank from Stanford Medicine in Stanford, CA, about the recent advancements in testing for Minimal/Measurable Residual Disease (MRD). In this episode, we delve into what MRD is, which blood cancers testing is currently used on, and how we can utilize it to more accurately monitor patients and customize treatment. The doctors also share exciting possibilities on how MRD and other testing can benefit patients in the future.

CLICK HERE to participate in our episode survey.

Mentioned on this episode:

Additional LLS Support Resources:

Support for this episode provided by Genentech, Inc. and Biogen.


  1. This is informative podcast is encouraging, upbeat and in language that is accessible to most patients. What a gift to us: lymphoma and leukemia patients.

    Dr. Frank has been my doctor for many years now, since his days as a fellow in the lymphoma clinic. He guide me through CAR-T therapy one year ago (at the height of terror about COVID) and continues to provide compassionate, non-paternalistic care. He practices what he says, especially about the best way to care for patients… the end of this excellent session. I realize those of us with access to doctors like Drs. Frank and Muffly, and to cancer centers like Stanford”s — are exceedingly fortunate. I hope for the day when these procedures are available to the majority of patients… not only the fortunate few.

Leave a Comment

Your email address will not be published. Required fields are marked *